Cargando…

BET inhibitors: Betting on improved outcomes in uterine serous carcinoma

Detalles Bibliográficos
Autores principales:	Zeybek, Burak, Lopez, Salvatore, Santin, Alessandro D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6231456/ https://www.ncbi.nlm.nih.gov/pubmed/30464799 http://dx.doi.org/10.18632/oncotarget.26245

Ejemplares similares

Targeting Her2/neu in uterine serous carcinoma: A paradigm shift in management
por: Lopez, Salvatore, et al.
Publicado: (2018)

To Bet or Not to Bet on T-bet As a Therapeutic Target in Emphysema?
por: Wang, Xiaoyun, et al.
Publicado: (2019)

How Much Can We Bet on Activity of BET Inhibitors Beyond NUT–Midline Carcinoma?
por: Martin-Romano, Patricia, et al.
Publicado: (2019)

BET in Pulmonary Arterial Hypertension: Exploration of BET Inhibitors to Reverse Vascular Remodeling
por: Dai, Zhiyu, et al.
Publicado: (2019)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

BET bromodomain inhibitor (JQ1) and tumor angiogenesis
por: Bid, Hemant Kumar, et al.
Publicado: (2016)

Lifetime Prediction of Polymers: To Bet, or Not to Bet—Is This the Question?
por: Blanco, Ignazio
Publicado: (2018)

BETting on combination to overcome PARPi resistance
por: Zhang, Youyou, et al.
Publicado: (2017)

Improved survival of patients with hypermutation in uterine serous carcinoma
por: Santin, Alessandro D., et al.
Publicado: (2015)

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
por: Pelligra, Silvia, et al.
Publicado: (2020)

Elongation vs stalling: place your BET
por: Donato, Elisa, et al.
Publicado: (2017)

Early intervention in mental health: The best bet
por: The Lancet Regional Health – Southeast Asia
Publicado: (2022)

Design and Characterization of Bivalent BET Inhibitors
por: Tanaka, Minoru, et al.
Publicado: (2016)

Learning Not to Bet
por: Seager, Philip
Publicado: (1969)

BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2020)

Bet‐hedging and best‐bet strategies shape seed dormancy
por: Pausas, Juli G., et al.
Publicado: (2022)

Determinants of problem sports betting among college students: moderating roles of betting frequency and impulsive betting tendency
por: Shen, Yawen
Publicado: (2023)

Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors
por: Janouskova, Hana, et al.
Publicado: (2017)

Intrinsic BET inhibitor resistance in prostate cancer caused by SPOP mutation-mediated BET protein stabilization
por: Zhang, Pingzhao, et al.
Publicado: (2017)

Happy 25th birthday, Bet v 1!
por: Jensen-Jarolim, Erika
Publicado: (2014)

The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

BET protein Brd4 activates transcription in neurons and BET inhibitor Jq1 blocks memory in mice
por: Korb, Erica, et al.
Publicado: (2015)

Transcriptome analysis of iBET-151, a BET inhibitor alone and in combination with paclitaxel in gastric cancer cells
por: Kang, Sun Kyoung, et al.
Publicado: (2020)

Retraction Note: BET inhibitor I-BET151 sensitizes GBM cells to temozolomide via PUMA induction
por: Yao, Zhicheng, et al.
Publicado: (2022)

Betting is Loving and Bettors are Predators: A Conceptual Metaphor Approach to Online Sports Betting Advertising
por: Lopez-Gonzalez, Hibai, et al.
Publicado: (2017)

Bet hedging in the underworld
por: Zhang, Xue-Xian, et al.
Publicado: (2010)

Catching BETs by viruses
por: Zandian, Mohamad, et al.
Publicado: (2022)

Betting, Selection, and Luck: A Long-Run Analysis of Repeated Betting Markets
por: Bottazzi, Giulio, et al.
Publicado: (2019)

The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine
por: Xie, Fang, et al.
Publicado: (2018)

BETting on a new prostate cancer treatment
por: Asangani, Irfan A, et al.
Publicado: (2014)

HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma
por: McNamara, Blair, et al.
Publicado: (2023)

BET Inhibition Improves NASH and Liver Fibrosis
por: Middleton, Sarah A., et al.
Publicado: (2018)

“Betting on nature” or “betting on others”: anti-coordination induces uniquely high levels of entropy
por: Chierchia, Gabriele, et al.
Publicado: (2018)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
por: Taniguchi, Yasushi
Publicado: (2016)

When are the BET factors the most sensitive to bromodomain inhibitors?
por: Khochbin, Saadi
Publicado: (2013)

BET inhibitors as novel therapeutic agents in breast cancer
por: Ocaña, Alberto, et al.
Publicado: (2017)

Chemical probes and inhibitors of bromodomains outside the BET family
por: Moustakim, Moses, et al.
Publicado: (2016)

Role of BET Inhibitors in Triple Negative Breast Cancers
por: Khandekar, Durga, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qtv7161a0icf80hk23p4o9l1l0